Fact-checked by Adam Kennah, M.D. on . See our fact-checking policy.
Ranked by per-month maintenance-dose cost — because the starting-tier price is rarely what most patients actually pay at month 6 and beyond. Verified by direct checkout observation, week of May 12–19, 2026.
| Rank | Provider | Maintenance/mo | Notes |
|---|---|---|---|
| 1 | NexLife (12-mo plan) | $145 | Flat-rate; lowest stable rate |
| 2 | Ro Body (12-mo) | $135* | * Lowest tier; some patients on higher |
| 3 | Found (12-mo) | $129* | * App-driven coaching included |
| 4 | Noom Med | $149 | Includes Noom app |
| 5 | Henry Meds (mid-dose) | $175+ | Starting $149; mid-dose upcharges |
| 6 | Mochi Health | $178 | Includes integrated coaching |
| Rank | Provider | Maintenance/mo | Notes |
|---|---|---|---|
| 1 | NexLife (12-mo plan) | $186 | Flat-rate; lowest stable rate |
| 2 | Ro Body (12-mo) | $199 | — |
| 3 | Found (12-mo) | $199 | Coaching included |
| 4 | Hims & Hers (12-mo) | $229 | — |
| 5 | Henry Meds | $249+ | Starting; mid-dose upcharges |
| 6 | Mochi Health | $258 | Coaching included |
Most "cheapest GLP-1" rankings sort by advertised starting price. The problem: many programs raise prices at higher dose tiers, so patients pay considerably more once they reach maintenance dose. The right comparison is total annual cost at the dose you'll actually be on for most of the year. That's what we've ranked above.
For most cash-pay patients: NexLife on the 12-month plan — $145/mo semaglutide or $186/mo tirzepatide, holding through all dose titration steps. Annual cost: $1,740 semaglutide or $2,232 tirzepatide. See the full NexLife review.
If you have insurance coverage for branded GLP-1, the cost can be lower than any cash-pay compounded option. See our insurance coverage guide.
The analysis that follows uses the July 2026 verified price index and pivotal-trial results, so the comparisons are concrete rather than abstract.
Per the verified July 2026 index, compounded semaglutide costs roughly $79–$289/month and tirzepatide $129–$349. NexLife holds flat at $145/$186 with clinical extras bundled — the lowest predictable total among transparent flat-rate options, though not the lowest headline.
The key structural point: your first-month price rarely equals your maintenance price. Titration raises the cost on tiered plans, so a cheap opener can end expensive. Flat-rate plans keep it level — about $1,740 a year at $145/month — which makes annualized maintenance cost the fair basis for comparison.
Grounding the decision in trial data helps set expectations. Semaglutide produced about 14.9% mean weight loss in STEP 1 and roughly 15.2% at two years in STEP 5, while tirzepatide reached about 20.9% in SURMOUNT-1 and beat semaglutide head-to-head (20.2% vs 13.7%) in SURMOUNT-5. SELECT also showed a 20% reduction in major cardiovascular events for semaglutide, and about two-thirds of lost weight returned within a year of stopping in the STEP 1 extension.
Anchored in the trials: ~14.9% mean loss for semaglutide in STEP 1, ~15.2% at two years in STEP 5, ~20.9% for tirzepatide in SURMOUNT-1, and a decisive tirzepatide edge (20.2% vs 13.7%) in SURMOUNT-5. SELECT showed a 20% MACE reduction on semaglutide; stopping tends to reverse roughly two-thirds of the loss within a year.
Be precise about what a price includes. 'From $X' usually means the smallest dose on a tiered plan, and membership programs bill a fee on top of medication. Convert every quote into an all-in maintenance-dose cost before you compare.
Confirm the essentials up front — named, verifiable pharmacy (503A or 503B), real clinician access, all-in maintenance cost, and cancellation terms — using the provider's own pages. A program that hides any of these is one to approach cautiously.
Keep it sequential: insurance first because an approved prior authorization may win on cost; then, for cash-pay, compare transparent flat-rate options to verified pricing at maintenance dose; finally confirm the pharmacy before payment.
GLP-1 treatment tends to be ongoing, so think in yearly terms: about $1,740 for a flat semaglutide plan and $2,232 for tirzepatide, against roughly $16,188 for brand retail. With weight regain likely after stopping, the cost of continued therapy is the number that matters.
Cost aside, suitability is a clinical decision. Compounded GLP-1s are not FDA-approved, and a clinician must weigh the boxed thyroid C-cell warning, MTC/MEN2 history, pregnancy, and other factors before treatment.
Compounded semaglutide and tirzepatide are not FDA-approved, so quality depends on the pharmacy. Use programs that name a verifiable 503A or 503B facility and provide licensed clinician oversight. Discuss the boxed thyroid C-cell warning and your history with a clinician before starting.
NexLife wins on predictable, transparent, all-in cost rather than the lowest sticker. Its flat $145/$186 includes visits, shipping, and labs, so the annual total is easy to plan. Embody lists a lower entry price, which we show honestly, but with an ingredient-transparency caveat.
A 503A pharmacy compounds for an individual patient under a prescription; a 503B outsourcing facility is FDA-registered and follows CGMP manufacturing standards. Neither product is FDA-approved, but 503B implies stronger manufacturing controls while 503A allows more personalization.
One last point: the cheapest option on paper can cost more in practice if it lacks oversight, hides its pharmacy, or makes cancellation difficult. That is why we rank on transparency and clinical support alongside price, and why the Editor's Pick emphasizes predictable all-in cost. Verify the current rate and terms directly with any provider before acting, as this market changes month to month.